Core Viewpoint - Kingchem (Liaoning) Life Science Co., Ltd. reported significant growth in its financial performance for the first half of 2025, with notable increases in revenue and net profit compared to the same period last year [1][2]. Financial Performance - The company's operating revenue reached CNY 348,402,686.20, marking a 32.98% increase from CNY 261,993,494.68 in the previous year [1]. - Net profit attributable to shareholders was CNY 71,760,596.20, representing a substantial increase of 123.61% from CNY 32,091,742.08 [1]. - The net profit after deducting non-recurring gains and losses was also significantly higher, although specific figures were not provided [1]. - The net cash flow from operating activities was CNY 74,718,846.77, up 14.47% from CNY 65,272,793.61 [1]. - Basic and diluted earnings per share both increased to CNY 0.60, a rise of 122.22% from CNY 0.27 [1]. Asset and Equity Position - Total assets at the end of the reporting period were CNY 2,303,635,543.06, reflecting a 1.78% increase from CNY 2,263,389,145.02 at the end of the previous year [2]. - Net assets attributable to shareholders increased to CNY 2,173,929,045.13, a growth of 1.17% from CNY 2,148,819,290.03 [2]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 13,817 [2]. - The largest shareholder, Kingchem (China) Holding LLC, holds 48.66% of the shares, with FUMIN WANG and LIANPING WU having a controlling interest [3][4]. - There were no changes in the controlling shareholder or actual controller during the reporting period [4].
金凯生科: 2025年半年度报告摘要